Expression of MHC class I and class II antigens in pancreatic adenocarcinomas

Tissue Antigens

Volumn 48, Issue 4 I, 1996, Pages 301-311

  Scupoli, M T ^a   Sartoris, S ^a   Tosi, G ^e   Ennas, M G ^b   Nicolis, M ^a   Cestari, T ^a   Zamboni, G ^a   Martignoni, G ^a   Lemoine, N R ^c   Scarpa, A ^a   Accolla, R S ^d,e  

^a UNIVERSITY OF VERONA   (Italy)

^b UNIVERSITY OF CAGLIARI   (Italy)

^c HAMMERSMITH HOSPITAL   (United Kingdom)

^d UNIVERSITY OF PAVIA   (Italy)

^e U of Cell and Molecular Genetics   (Italy)

Author keywords

Expression; HLA; Pancreatic tumors; Tumor heterogeneity

Indexed keywords

CELL SURFACE PROTEIN; HLA ANTIGEN CLASS 2; HLA DP ANTIGEN; HLA DQ ANTIGEN; HLA DR ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ADULT; AGED; ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; ARTICLE; CELL CLONE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOREGULATION; MALE; METASTASIS POTENTIAL; PANCREAS ADENOCARCINOMA; PHENOTYPE; PRIORITY JOURNAL;

EID: 10344248944     PISSN: 00012815     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-0039.1996.tb02649.x     Document Type: Article

References (45)

1. Benacerraf B. Role of the MHC products in immune regulation. Science 1981: 212: 1229-38.
2. Zinkernagel RM, Doherty PC. MHC cytotoxic T cells: studies on the biological role of polymorphic major transplantation antigens determining T cell restriction-specificity, function and responsiveness. Adv Immunol 1979: 27: 51-177.
3. Townsend A, Ohlen C, Bastin J, Ljunggren HG, Foster L, Karre K. Association of class I major histocompatibility heavy and light chains induced by viral peptides. Nature 1989: 340: 443-8.
4. Accolla RS, Scupoli MT, Cambiaggi C, Tosi G, Sartoris S. Cell lineage-specific and developmental stage-specific controls of MHC class II antigen expression. Int J Cancer 1991: s.6: 20-5.
5. Doyle A, Martin WJ, Funa K et al. Markedly decreased expression of class I histocompatibility antigens, protein, and mRNA in human small-cell lung cancer. J Exp Med 1985: 161: 1135-51.
6. 2-microglobulin on human neuroblastoma cell lines. J Immunol 1983: 130: 2471-78.
7. Momburg F, Degener T, Bacchus E, Moldenhauer G, Hämmerling G. Möller P. Loss of HLA-A, -B, -C and de novo expression of HLA-D in colorectal cancer. Int J Cancer 1986: 37: 179-84.
8. Momburg F, Ziegler A, Harpprecht J, Möller P, Moldenhauer G, Hämmerling G. Selective loss of HLA-A or HLA-B antigen in colon carcinoma. J Immunol 1989: 142: 352-8.
9. Ruiter DJ, Bergman W, Welvaart K et al. Immunohistochemical analysis of malignant melanomas and nevocellular nevi with monoclonal antibodies to distinct monomorphic determinants of HLA antigens. Cancer Res 1984: 44: 3930-5.
10. Bhan AK, DesMarias CL. Immunohistological characterization of major histocompatibility antigens and inflammatory cellular infiltrate in human breast cancer. J Natl Cancer Inst 1983: 71: 507-11.
11. Garrido F, Cabrera T, Concha A, Glew S, Ruiz-Cabello F, Stern PL. Natural history of HLA expression during tumour development. Immunol Today 1993: 14: 491-9.
12. Bernards R, Dessain SK, Weinerg RA. N-myc amplification causes down-modulation of MHC class I antigen expression in neuroblastoma. Cell 1986: 47: 667-74.
13. Versteeg R, Noordermeer IA, Krüse-Wolters M, Ruiter DJ, Schrier PI. c-myc down regulates class I HLA expression in human melanomas. EMBO J 1988: 7: 1023-29.
14. Versteeg R, Kruse-Wolters KM, Plomp AC et al. Suppression of class I human histocompatibility leucocyte antigen by c-myc is locus specific. J Exp Med 1989: 170: 621-35.
15. Albino AP, Houghton AN, Eisinger M et al. Class II histocompatibility antigen expression in human melanocytes transformed by Harvey murine sarcoma virus (Ha-MSV) and Kirstein MSV retrovirus. J Exp Med 1986: 164: 1710-22.
16. Lopez-Nevot MA, Garcia E, Romero C, Oliva MR, Serrano S, Garrido F. Phenotypic and genetic analysis of HLA class I and HLA-DR antigen expression on human melanomas. Exp Clin Immunogenet 1988: 5: 203-12.
17. Concha A, Esteban F, Cabrera T, Ruiz-Cabello F, Garrido F. Tumor aggressiveness and MHC class I and II antigens in laryngeal and breast cancer. Semin Cancer Biol 1991: 2: 47-54.
18. Brunner CA, Gokel JM, Riethmuller H, Johnson JP. Expression of HLA-D subloci DR and DQ by breast carcinomas is correlated with distinct parameters of favourable prognois. Eur J Cancer 1991: 27: 411-6.
19. Warshaw A, Castillo CFD. Pancreatic carcinoma. N Engl J Med 1992: 326: 455-65.
20. Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 1988: 53: 549-54.
21. Barton CM, Staddon SL, Hughes CM et al. Abnormalities of the p53 tumor suppressor gene in human pancreatic cancer. Br J Cancer, 1991: 64: 1076-82.
22. Scarpa A, Capelli P, Mukai K et al. Pancreatic adenocarcinomas frequently show p53 gene mutation. Am J Pathol 1993: 142: 1534-43.
23. Maillet B, De Grève J, Lemoine N, Kalthoff H, Schmiegel W, Klöppel GV. Genetic alterations. Phenotypical differentiation and genetic alterations in human pancreatic carcinoma cell lines. Int J Pancreatol 1993: 14: 72-5.
24. Lemonnier FA, Rebaj N, Le Bouteiller PP, Malissen B, Caillol DH, Kourilsky PM. Epitopic analysis of detergent-solubilized HLA molecules by solid-phase radioimmunoassay. J Immunol Methods 1982: 54: 9-22.
25. Accolla RS, Gross N, Carrel S, Corte G. Distinct forms of both and subunits are present in the human Ia molecular pool. Proc Natl Acad Sci U S A 1981: 78: 4549-4551.
26. Watson AJ, De Mars R, Trowbridge IS, Bach FH. Detection of a novel human class II HLA antigen. Nature (London) 1983: 304: 358-361.
27. Corte G, Calabi F, Damiani G, Bargellesi A, Tosi R, Sorrentino R. Human Ia molecules carrying DC1 determinants differ in both and subunits from Ia molecules carrying DR determinants. Nature (London) 1981: 292: 357-360.
28. Mattiuz L, Cambon-Thomsen A, Goeken N, Kaplan C, Calot. Antigen Society # 26 Report (DR3, DR7, DQw2): Part 4: HLA-DQw2. In: Dupont B, ed. Immunobiology of HLA. New York: Springer-Verlag, 1989: 1: 263-6.
29. Tait D, Park MS, Barbetti A, Langley J, Terasaki PI, Aizawa M. Antigen Society # 28 Report (DQw3). In: Dupont B, ed. Immunobiology of HLA. New York: Springer-Verlag, 1989: 1: 269-73.
30. Scarpa A, Capelli P, Zamboni G et al. Neoplasia of the ampulla of Vater. Am J Pathol 1993: 142: 1163-72.
31. Maniatis T, Fritsch E, Sambrook J. Molecular cloning: a laboratory manual. Cold Spring Harbor: Cold Spring Harbor Laboratory, 1982.
32. Sartoris S, Scupoli MT, Scarpellino L et al. Inducible and constitutive MHC class II gene expression. J Immunol 1991: 145: 1960-67.
33. Daar AS, Fuggle SV, Fabre JW, Ting A, Morris PJ. The detailed distribution of HLA-A, B, C antigens in normal human organs. Transplantation 1984: 38: 287-92.
34. Daar AS, Fuggle SV, Fabre JW, Ting A, Morris PJ. The detailed distribution of MHC class II antigens in normal human organs. Transplantation 1984: 38: 293-8.
35. Bedossa P, Bacci J, Lamaigre G, Martin E. Lymphocyte subset and HLA-DR expression in normal pancreas and chronic pancreatitis. Pancreas 1990: 5: 415-20.
36. Robinson J, Sieff C, Delia D, Edwards PAW, Greaves MF. Expression of cell surface HLA-DR, HLA-ABC and glycophorin during erythroid differentiation. Nature 1981: 289: 68-71.
37. Falkenburg JHF, Jansen J, van der Vaart-Duinkerken N et al. Polymorphic and monomorphic HLA-DR determinants on human hematopoietic progenitor cells. Blood 1984: 63: 1125-30.
38. Lucey DR, Nicholson-Weller A, Weller PH. Mature human eosinophils have the capacity to express HLA-DR. Proc Natl Acad Sci U S A 1989: 86: 1348-53.
39. Sakai K, Takiguchi M, Mori S et al. Expression and function of class II antigens on gastric carcinoma cells and gastric epithelia: differential expression of DR, DQ, and DP antigens. J Natl Cancer Inst 1987: 52: 4009-16.
40. Gutierrez J, Lopez-Nevot MA, Cabrera T et al. Class I and class II HLA antigen distribution in normal mucosa, adenoma and coloncarcinoma: relation with malignancy and invasiveness. Exp Clin Immunogenet 1987: 4: 144-52 .
41. Paterson AC, Sciot R, Kew MC, Callea F, Dusheiko GM, Desmet VJ. HLA expression in hepatocellular carcinoma. Br J Cancer 1988: 57: 369-73.
42. Glew SS, Duggan-Keen M, Cabrera T, Stern PL. HLA class II antigen expression in human papillomavirus-associated cervical cancer. Cancer Res 1992: 52: 4009-16.
43. van Vreeswijk H, Ruiter DJ, Brocker EB, Welvaart K, Ferrone S. Differential expression of HLA-DR , DQ, and DP antigens in primary and metastatic melanomas. J Invest Dermatol 1988: 90: 755-60.
44. Anichini A, Castelli C, Sozzi G, Fossati G, Parmiani G. Differential supsceptibility to recombinant IFN-induced HLA-DQ antigen modulation among clones from a human metastatic melanoma. J Immunol 1988: 140: 183-91.
45. De Lerma Barbaro A, Sartoris S, Tosi G, Nicolis M, Accolla RS. Evidence of a specific post-transcriptional mechanism controlling the expression of HLA-DQ, but not -DR and -DP, molecules. J Immunol 1994: 153: 4530-8.